Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319263 | 0.85 | HPGD (0.65) | CYP3A4ALDH1A1ALOX15TDP1HPGD | |
| SCHEMBL28782035 | 0.85 | AKR1B1 (0.49) | CYP3A4ALDH1A1ALOX15TDP1HPGD | |
| SCHEMBL3845094 | 0.83 | MEN1 (0.53) | CYP3A4ALDH1A1ALOX15TDP1HPGD | |
| SCHEMBL3844596 | 0.82 | MEN1 (0.52) | CYP3A4ALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL3358491 | 0.82 | MEN1 (0.55) | CYP3A4ALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL3358389 | 0.82 | KMT2A (0.59) | CYP3A4ALDH1A1ALOX15TDP1HPGD | |
| SCHEMBL3360184 | 0.80 | GAA (0.56) | CYP3A4ALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL7425506 | 0.80 | CYP3A4 (0.49) | CYP3A4ALDH1A1ALOX15TDP1HPGD | |
| SCHEMBL7655824 | 0.80 | HPGD (0.61) | CYP3A4ALDH1A1ALOX15TDP1HPGD | |
| SCHEMBL3843872 | 0.78 | HPGD (0.64) | CYP3A4HPGDCYP1A2CYP2C19AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105283-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20080255161-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255161-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, ECHS1 | CYP3A4 422/4885ALDH1A1 994/4885ALOX15 194/4885 |
| US-20090105283-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, ECHS1 | CYP3A4 422/4885ALDH1A1 994/4885ALOX15 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.